| Identification | Back Directory | [Name]
Deferiprone-d3 | [CAS]
1346601-82-8 | [Synonyms]
DMHP-d3
CP-20-d3
Kelfer-d3
Deferiprone-d3
[2H3]-Deferiprone
TZXKOCQBRNJULO-BMSJAHLVSA-N
1,2-DiMethyl-3-hydroxypyrid-4-one-d3
3-Hydroxy-1,2-diMethyl-4(1H)-pyridinone-d3
Deferiprone D3Q: What is
Deferiprone D3 Q: What is the CAS Number of
Deferiprone D3 Q: What are the applications of
Deferiprone D3 | [Molecular Formula]
C7H9NO2 | [MDL Number]
MFCD19704955 | [MOL File]
1346601-82-8.mol | [Molecular Weight]
139.15 |
| Chemical Properties | Back Directory | [Melting point ]
>244°C (dec.) | [storage temp. ]
-20°C Freezer | [solubility ]
Methanol (Slightly, Heated), Water (Slightly, Heated) | [form ]
Solid | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
Deferiprone-d3 is intended for use as an internal standard for the quantification of deferiprone by GC- or LC-MS. Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities. It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 μM, respectively. Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase 3β (GSK3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg. Formulations containing deferiprone have been used in the treatment of thalassemia. | [Uses]
A chelator that could replace disferrioxamine. It is orally and parenterally effective in the removal of iron in vivo from rabbits and mice and also from transferrin and ferritin in vitro. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Kontoghiorghes GJ, et al. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26(8):553-584. DOI:10.2165/00002018-200326080-00003 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|